# Next Generation Translational Proteomics for Alzheimer's and Related Dementias

> **NIH NIH U19** · UNIVERSITY OF WASHINGTON · 2020 · $3,351,008

## Abstract

Abstract
Alzheimer's disease (AD) is a major, growing global public health problem. This is a daunting scientific
challenge and solutions will come only from innovative research. We have brought together a unique
interdisciplinary team of investigators with the goal of bridging the divide between state-of-the-art technologies
and translational applications.
To monitor AD disease progression or response to treatment, cerebrospinal fluid (CSF) represents the
preferred fluid to reflect brain pathophysiology. The brain interstitial fluid is in direct contact with the CSF by
unrestricted bidirectional flow of proteins and the CSF is protected from the peripheral system because of the
 𝛽
restricted transportation of molecules and proteins by the blood-brain barrier. Known CSF biomarkers have
been demonstrated to reflect the three main pathological changes that occur in the AD brain -- amyloid-
deposition, neurofibrillary degeneration, and neuronal injury. Therefore, analysis of molecules and particles in
CSF holds the greatest potential to improve our diagnosis and characterization of neurodegenerative diseases
in vivo.
We propose to enable precision medicine for AD by developing a cooperative research program that will unite
a unique research team with the specific goal of vastly improving the molecular characterization of CSF as
predictors of cognitive decline and AD pathophysiology. The efforts of this program will complement existing
efforts to accelerate the identification and validation of clinically relevant therapeutic targets. We will work in
parallel with programs like Accelerating Medicines Partnership (AMP) and the AD Centers Program, to provide
unique diagnostic capabilities in support of the process of bringing new medicines to patients.
Our U19 research program will consist of four projects and four cores that are synergistic to our mission.
Moreover, our research team is uniquely suited to the development, validation and translational application of
new biomolecular assays to reflect AD pathophysiology. This U19 will harness the collective expertise of
multiple fields, combined with the financial resources sufficient to extend and apply next generation proteomics
technologies to clinical specimens that have been extensively annotated with longitudinal, consensus clinical
diagnostic and neuropsychological test data. We will create new assays with the goal of deployment to the
clinical lab. We will create unique and sustainable reagents that will facilitate dissemination and deployment of
these methods worldwide. Our program will expand existing infrastructure, developed by our labs, for sharing
and disseminating these data and protocols. The application of new technologies, development of novel
reagents, creation of new clinical assays, and dissemination of data and protocols will accelerate neuroscience
in a way not feasible under traditional NIH mechanisms.

## Key facts

- **NIH application ID:** 9854149
- **Project number:** 1U19AG065156-01
- **Recipient organization:** UNIVERSITY OF WASHINGTON
- **Principal Investigator:** Michael MacCoss
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $3,351,008
- **Award type:** 1
- **Project period:** 2020-02-15 → 2025-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9854149

## Citation

> US National Institutes of Health, RePORTER application 9854149, Next Generation Translational Proteomics for Alzheimer's and Related Dementias (1U19AG065156-01). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9854149. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*